Texmaco Rail & Engineering Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 8, 2025, 4:11 am

Competitors of Texmaco Rail & Engineering Ltd

All Competitor Stocks of Texmaco Rail & Engineering Ltd

Quarterly Result

Last Updated: August 20, 2025, 2:30 am

Below is a detailed analysis of the quarterly data for Texmaco Rail & Engineering Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 807.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,140.00 Cr. (Mar 2025) to 807.00 Cr., marking a decrease of 333.00 Cr..
• For Expenses, as of Jun 2025, the value is 749.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,077.00 Cr. (Mar 2025) to 749.00 Cr., marking a decrease of 328.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 63.00 Cr. (Mar 2025) to 57.00 Cr., marking a decrease of 6.00 Cr..
• For OPM %, as of Jun 2025, the value is 7.00%. The value appears strong and on an upward trend. It has increased from 6.00% (Mar 2025) to 7.00%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 24.00 Cr..
• For Interest, as of Jun 2025, the value is 30.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 33.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 62.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 27.00 Cr..
• For Tax %, as of Jun 2025, the value is 33.00%. The value appears to be improving (decreasing) as expected. It has decreased from 42.00% (Mar 2025) to 33.00%, marking a decrease of 9.00%.
• For Net Profit, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 36.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 12.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.59. The value appears to be declining and may need further review. It has decreased from 0.91 (Mar 2025) to 0.59, marking a decrease of 0.32.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:18 am

Growth

Last Updated: September 5, 2025, 1:41 pm

Balance Sheet

Last Updated: September 10, 2025, 2:38 pm

Below is a detailed analysis of the balance sheet data for Texmaco Rail & Engineering Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 40.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 40.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,632.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,446.00 Cr. (Mar 2024) to 2,632.00 Cr., marking an increase of 186.00 Cr..
• For Borrowings, as of Mar 2025, the value is 871.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 631.00 Cr. (Mar 2024) to 871.00 Cr., marking an increase of 240.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 855.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,023.00 Cr. (Mar 2024) to 855.00 Cr., marking a decrease of 168.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 4,398.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,140.00 Cr. (Mar 2024) to 4,398.00 Cr., marking an increase of 258.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 449.00 Cr.. The value appears strong and on an upward trend. It has increased from 399.00 Cr. (Mar 2024) to 449.00 Cr., marking an increase of 50.00 Cr..
• For CWIP, as of Mar 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2024) to 31.00 Cr., marking an increase of 10.00 Cr..
• For Investments, as of Mar 2025, the value is 837.00 Cr.. The value appears strong and on an upward trend. It has increased from 408.00 Cr. (Mar 2024) to 837.00 Cr., marking an increase of 429.00 Cr..
• For Other Assets, as of Mar 2025, the value is 3,082.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,312.00 Cr. (Mar 2024) to 3,082.00 Cr., marking a decrease of 230.00 Cr..
• For Total Assets, as of Mar 2025, the value is 4,398.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,140.00 Cr. (Mar 2024) to 4,398.00 Cr., marking an increase of 258.00 Cr..

Notably, the Reserves (2,632.00 Cr.) exceed the Borrowings (871.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Texmaco Rail & Engineering Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 6.24. This value is within the healthy range. It has increased from 3.29 (Mar 24) to 6.24, marking an increase of 2.95.
• For Diluted EPS (Rs.), as of Mar 25, the value is 6.21. This value is within the healthy range. It has increased from 3.29 (Mar 24) to 6.21, marking an increase of 2.92.
• For Cash EPS (Rs.), as of Mar 25, the value is 6.73. This value is within the healthy range. It has increased from 3.36 (Mar 24) to 6.73, marking an increase of 3.37.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 69.10. It has increased from 62.49 (Mar 24) to 69.10, marking an increase of 6.61.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 70.02. It has increased from 63.41 (Mar 24) to 70.02, marking an increase of 6.61.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 127.83. It has increased from 87.69 (Mar 24) to 127.83, marking an increase of 40.14.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 13.14. This value is within the healthy range. It has increased from 8.34 (Mar 24) to 13.14, marking an increase of 4.80.
• For PBIT / Share (Rs.), as of Mar 25, the value is 12.06. This value is within the healthy range. It has increased from 7.38 (Mar 24) to 12.06, marking an increase of 4.68.
• For PBT / Share (Rs.), as of Mar 25, the value is 8.63. This value is within the healthy range. It has increased from 4.06 (Mar 24) to 8.63, marking an increase of 4.57.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 2.41 (Mar 24) to 5.65, marking an increase of 3.24.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.24. This value is within the healthy range. It has increased from 2.83 (Mar 24) to 6.24, marking an increase of 3.41.
• For PBDIT Margin (%), as of Mar 25, the value is 10.27. This value is within the healthy range. It has increased from 9.50 (Mar 24) to 10.27, marking an increase of 0.77.
• For PBIT Margin (%), as of Mar 25, the value is 9.43. This value is below the healthy minimum of 10. It has increased from 8.41 (Mar 24) to 9.43, marking an increase of 1.02.
• For PBT Margin (%), as of Mar 25, the value is 6.74. This value is below the healthy minimum of 10. It has increased from 4.63 (Mar 24) to 6.74, marking an increase of 2.11.
• For Net Profit Margin (%), as of Mar 25, the value is 4.41. This value is below the healthy minimum of 5. It has increased from 2.74 (Mar 24) to 4.41, marking an increase of 1.67.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.87. This value is below the healthy minimum of 8. It has increased from 3.23 (Mar 24) to 4.87, marking an increase of 1.64.
• For Return on Networth / Equity (%), as of Mar 25, the value is 9.02. This value is below the healthy minimum of 15. It has increased from 4.53 (Mar 24) to 9.02, marking an increase of 4.49.
• For Return on Capital Employeed (%), as of Mar 25, the value is 14.74. This value is within the healthy range. It has increased from 10.33 (Mar 24) to 14.74, marking an increase of 4.41.
• For Return On Assets (%), as of Mar 25, the value is 5.15. This value is within the healthy range. It has increased from 2.70 (Mar 24) to 5.15, marking an increase of 2.45.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 0.2. It has increased from 0.09 (Mar 24) to 0.12, marking an increase of 0.03.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.33. This value is within the healthy range. It has increased from 0.25 (Mar 24) to 0.33, marking an increase of 0.08.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.13. It has increased from 0.92 (Mar 24) to 1.13, marking an increase of 0.21.
• For Current Ratio (X), as of Mar 25, the value is 2.28. This value is within the healthy range. It has decreased from 2.61 (Mar 24) to 2.28, marking a decrease of 0.33.
• For Quick Ratio (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 1.74, marking a decrease of 0.32.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.48. This value is within the healthy range. It has increased from 5.00 (Mar 24) to 6.48, marking an increase of 1.48.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 8.01. This value is below the healthy minimum of 20. It has increased from 4.26 (Mar 24) to 8.01, marking an increase of 3.75.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.83. This value is below the healthy minimum of 20. It has increased from 3.18 (Mar 24) to 6.83, marking an increase of 3.65.
• For Earning Retention Ratio (%), as of Mar 25, the value is 91.99. This value exceeds the healthy maximum of 70. It has decreased from 95.74 (Mar 24) to 91.99, marking a decrease of 3.75.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.17. This value exceeds the healthy maximum of 70. It has decreased from 96.82 (Mar 24) to 93.17, marking a decrease of 3.65.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 3.83. This value is within the healthy range. It has increased from 2.51 (Mar 24) to 3.83, marking an increase of 1.32.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 3. It has increased from 1.72 (Mar 24) to 2.64, marking an increase of 0.92.
• For Enterprise Value (Cr.), as of Mar 25, the value is 6,130.73. It has decreased from 6,810.79 (Mar 24) to 6,130.73, marking a decrease of 680.06.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.20. This value is within the healthy range. It has decreased from 1.94 (Mar 24) to 1.20, marking a decrease of 0.74.
• For EV / EBITDA (X), as of Mar 25, the value is 11.68. This value is within the healthy range. It has decreased from 20.45 (Mar 24) to 11.68, marking a decrease of 8.77.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has decreased from 1.88 (Mar 24) to 1.05, marking a decrease of 0.83.
• For Retention Ratios (%), as of Mar 25, the value is 91.98. This value exceeds the healthy maximum of 70. It has decreased from 95.73 (Mar 24) to 91.98, marking a decrease of 3.75.
• For Price / BV (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has decreased from 2.64 (Mar 24) to 1.95, marking a decrease of 0.69.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has decreased from 1.88 (Mar 24) to 1.05, marking a decrease of 0.83.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.04, marking an increase of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness